Q1 2019 13F Holders as of 31 Mar 2019
-
Type / Class
-
Equity / SHS
-
Total 13F shares
-
29,149,277
-
Share change
-
-3,062,558
-
Total reported value
-
$71,092,686
-
Put/Call ratio
-
0%
-
Price per share
-
$2.44
-
Number of holders
-
40
-
Value change
-
-$3,312,033
-
Number of buys
-
18
-
Number of sells
-
21
Institutional Holders of NABRIVA THERAPEUTICS PLC - SHS as of Q1 2019
As of 31 Mar 2019,
NABRIVA THERAPEUTICS PLC - SHS was held by
40 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,149,277 shares.
The largest 10 holders included
Novo Holdings A/S, ORBIMED ADVISORS LLC, Vivo Capital, LLC, FRAZIER MANAGEMENT LLC, FMR LLC, Aisling Capital Management LP, Rock Springs Capital Management LP, RENAISSANCE TECHNOLOGIES LLC, DIMENSIONAL FUND ADVISORS LP, and Fosun International Ltd.
This page lists
40
institutional shareholders reporting positions in this security
for the Q1 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.